Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AI-09
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eirion Shows AI-09 Neuromodulator Efficacy in Anti-Wrinkle Phase 1 Trial
Details : AI-0 is a liquid injectable neuromodulator currently being evaluated in early-stage clinical trials for the treatment of moderate to severe glabellar wrinkles.
Brand Name : AI-09
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : AI-09
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Botulinum Toxin
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AI-09 (botulinum toxin) employs a proprietary technology that allows an injectable botulinum to be formulated as a convenient, ready-to-use liquid product, instead of requiring reconstitution with saline prior to use.
Brand Name : AI-09
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 17, 2022
Lead Product(s) : Botulinum Toxin
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : HTL Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Details : As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axi...
Brand Name : ET-01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 08, 2021
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : HTL Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Shanghai Haohai Biological Technology
Deal Size : $40.0 million
Deal Type : Series A Financing
Details : One license is for Eirion's neuromodulator-based product candidates, ET-01 and AI-09 for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 and ET-03, which are intended for the treatment of hair loss and...
Brand Name : ET-01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 09, 2021
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Shanghai Haohai Biological Technology
Deal Size : $40.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?